Academic Radiology
Volume 17, Issue 4 , Pages 441-449 , April 2010

Dynamic Breast MRI in the Course of Neoadjuvant Chemotherapy: Standardized Evaluation of Tumor Size and Enhancement Parameters in Correlation to Different Histopathologic Characteristics

  • Thomas Schlossbauer, MD

      Affiliations

    • Institute for Clinical Radiology, University of Munich LMU, Marchioninistr. 15 81377 München, Germany
    • Corresponding Author InformationAddress correspondence to: T.S.
    • ,
  • Steven Sourbron, PhD

      Affiliations

    • Institute for Clinical Radiology, University of Munich LMU, Marchioninistr. 15 81377 München, Germany
    • ,
  • Anna Scholz

      Affiliations

    • Institute for Clinical Radiology, University of Munich LMU, Marchioninistr. 15 81377 München, Germany
    • ,
  • Marc Mosner, MD

      Affiliations

    • Department for Gynaecology, University of Munich LMU, Marchioninistr. 15 81377 München, Germany
    • ,
  • Steffen Kahlert, MD

      Affiliations

    • Department for Gynaecology, University of Munich LMU, Marchioninistr. 15 81377 München, Germany
    • ,
  • Holger Böhm, MD

      Affiliations

    • Institute for Clinical Radiology, University of Munich LMU, Marchioninistr. 15 81377 München, Germany
    • ,
  • Maximilian Reiser, MD

      Affiliations

    • Institute for Clinical Radiology, University of Munich LMU, Marchioninistr. 15 81377 München, Germany
    • ,
  • Karin Hellerhoff, MD

      Affiliations

    • Institute for Clinical Radiology, University of Munich LMU, Marchioninistr. 15 81377 München, Germany

Received 24 May 2009 ,Accepted 13 November 2009.

References 

  1. Shien T, Akashi-Tanaka S, Miyakawa K, et al. Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer. World J Surg. 2009;33:44–51
  2. Jeruss JS, Mittendorf EA, Tucker SL, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008;26:246–252
  3. Kuhl CK. The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology. 2007;244:672–691
  4. Beresford M, Padhani AR, Goh V, et al. Imaging breast cancer response during neoadjuvant systemic therapy. Expert Rev Anticancer Ther. 2005;5:893–905
  5. Makkat S, Luypaert R, Sourbron S, et al. Quantification of perfusion and permeability in breast tumors with a deconvolution-based analysis of second-bolus T1-DCE data. J Magn Reson Imaging. 2007;25:1159–1167
  6. Beresford MJ, Harris AL, Ah-See M, et al. The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br J Cancer. 2006;95:1683–1688
  7. Kuhl CK. Current status of breast MR imaging. Part 2. Clinical applications. Radiology. 2007;244:672–691
  8. Kuhl CK, Mielcareck P, Klaschik S, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?. Radiology. 1999;211:101–110
  9. Brix G, Kiessling F, Lucht R, et al. Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. Magnet Res Med. 2004;52:420–429
  10. Makkat S, Luypaert R, Stadnik T, et al. Deconvolution-based dynamic contrast-enhanced MR imaging of breast tumors: correlation of tumor blood flow with human epidermal growth factor receptor 2 status and clinicopathologic findings—preliminary results. Radiology. 2008;249:471–482
  11. Ferretti G, Felici A, Papaldo P, et al. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol. 2007;19:56–62
  12. Warm M, Kates R, Mallmann P, et al. Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer. Anticancer Res. 2007;27:1031–1038
  13. Chen SC, Chang HK, Lin YC, et al. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin. Jpn J Clin Oncol. 2008;38:99–105
  14. Schlossbauer T, Leinsinger G, Wismuller A, et al. Classification of small contrast enhancing breast lesions in dynamic magnetic resonance imaging using a combination of morphological criteria and dynamic analysis based on unsupervised vector-quantization. Invest Radiol. 2008;43:56–64
  15. Leinsinger G, Schlossbauer T, Scherr M, et al. Cluster analysis of signal-intensity time course in dynamic breast MRI: does unsupervised vector quantization help to evaluate small mammographic lesions?. Eur Radiol. 2006;16:1138–1146
  16. Kim HJ, Im YH, Han BK, et al. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI. Acta Oncol. 2007;46:996–1003
  17. Chou CP, Wu MT, Chang HT, et al. Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study. Acad Radiol. 2007;14:561–573
  18. Sourbron S, Michaely HJ, Reiser MF, et al. MRI-measurement of perfusion and glomerular filtration in the human kidney with a separable compartment model. Invest Radiol. 2008;43:40–48
  19. Makkat S, Luypaert R, Stadnik T, et al. Deconvolution-based dynamic contrast-enhanced MR imaging of breast tumors: correlation of tumor blood flow with human epidermal growth factor receptor 2 status and clinicopathologic findings—preliminary results. Radiology. 2008;249:471–482
  20. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138–140
  21. Drew PJ, Kerin MJ, Mahapatra T, et al. Evaluation of response to neoadjuvant chemotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. Eur J Surg Oncol. 2001;27:617–620
  22. Cheung YC, Wan YL, Lo YF, et al. Preoperative magnetic resonance imaging evaluation for breast cancers after sonographically guided core-needle biopsy: a comparison study. Ann Surg Oncol. 2004;11:756–761
  23. Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. Am J Roentgenol. 2005;184:868–877
  24. Akazawa K, Tamaki Y, Taguchi T, et al. Potential of reduction in total tumor volume measured with three-dimensional MRI as a prognostic factor for locally-advanced breast cancer patients treated with primary chemotherapy. Breast J. 2008;14:523–531

PII: S1076-6332(09)00633-3

doi: 10.1016/j.acra.2009.11.008

Academic Radiology
Volume 17, Issue 4 , Pages 441-449 , April 2010

Article Tools

* Image Usage & Resolution